Published within
|«
«
|
1
|
2
|
3
|
4
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
A small UK company has presented positive results from a Phase II trial investigating the use of bacteriophages for the treatment of Pseudomonas infections. The product, while still in the early stages of clinical development, represents a novel approach to the treatment of bacterial infections and offers a crucial new avenue of research in the treatment of Pseudomonas.
Published By Datamonitor
|
27 Feb 2008 |
|
CommentWire
|
Despite its advisory panel's recommendation, the FDA has granted accelerated approval for Avastin in HER2-negative metastatic breast cancer. A full approval can only be granted after the FDA reviews the results from further studies. However, it is unlikely that any new or unexpected safety concerns will be of sufficient significance to prevent full approval for Avastin in this indication.
Published By Datamonitor
|
27 Feb 2008 |
|
CommentWire
|
The FDA's non-approvable letter for istradefylline (KW-6002) represents a major setback for Kyowa Hakko. The company had intended for the novel drug to gain approval as an adjunctive treatment in advanced Parkinson's disease. However, the FDA's decision is good news for Eisai, as it will reduce competition to its late-stage Parkinson's disease compound, E2007.
Published By Datamonitor
|
28 Feb 2008 |
|
CommentWire
|
The fact that the New Drug Application for Theravance's antibiotic is being delayed by further investigations into monitoring issues at its study sites shows that the FDA is getting serious about reconsidering its drug approval processes.
Published By Datamonitor
|
04 Mar 2008 |
|
CommentWire
|
The continuing development of Zactima in non-small-cell lung cancer will be welcome news for AstraZeneca, following the recent failure of Recentin in the same indication. Success in this indication now hinges on whether Zactima's mechanism of action can translate into notable clinical benefit.
Published By Datamonitor
|
14 Mar 2008 |
|
CommentWire
|
Medivation is set to announce trial data regarding behavioral symptoms and the impact on caregivers relating to its Alzheimer's disease drug, Dimebon. Positive findings will enhance the validity of the impressive Phase II clinical trial data published in 2007. Dimebon is forecast for a 2011 launch, and is expected to account for 15% ($1.5 billion) of the $9.5 billion AD market by 2017.
Published By Datamonitor
|
14 Mar 2008 |
|
CommentWire
|
Basilea has received an approvable letter from the FDA for its new drug, ceftobiprole. Against the backdrop of investigations into the safety of Ketek, and considering the scrutiny Telavancin has endured, the letter is yet another indication of the FDA's more rigorous and defensive approach to the drug approval process.
Published By Datamonitor
|
18 Mar 2008 |
|
CommentWire
|
Vertex has completed a Phase II trial of a small-molecule oral drug, VX-770, which targets the basic defect that occurs in cystic fibrosis (CF). The trial has only been performed in 20 patients from a small, genetically distinct subset of the CF population. However, the results are encouraging and indicate an alternative approach to traditional reactive management of CF.
Published By Datamonitor
|
28 Mar 2008 |
|
CommentWire
|
Genentech has announced an update from the AVAiL Phase III study of Avastin in non-small cell lung cancer, showing improved progression-free survival. The proven efficacy of Avastin in combination with different chemotherapy regimens may lead to a modest increase in uptake, although the lack of overall survival benefit reported in this trial will leave it exposed to competition from Erbitux.
Published By Datamonitor
|
22 Apr 2008 |
|
CommentWire
|
According to the Infectious Disease Society of North America, the FDA has changed the 'breakpoints' used to determine the susceptibility cut-off for penicillins in the treatment of Streptococcus pneumoniae pneumonia. This will reinvigorate this largely genericized antibiotic class, and is indicative of increasing pressure on antibiotics as efforts are made to restrict antibiotic resistance.
Published By Datamonitor
|
30 Apr 2008 |
|
|«
«
|
1
|
2
|
3
|
4
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.